Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 392.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 169,111 shares of the biotechnology company's stock after buying an additional 134,791 shares during the period. Nuveen Asset Management LLC owned 0.37% of Capricor Therapeutics worth $2,334,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in Capricor Therapeutics by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 6,552 shares during the last quarter. Rhumbline Advisers raised its position in Capricor Therapeutics by 44.4% in the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock valued at $636,000 after purchasing an additional 14,169 shares during the period. New York State Common Retirement Fund raised its position in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the period. Black Diamond Financial LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $3,833,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Capricor Therapeutics by 32.6% during the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company's stock worth $1,160,000 after purchasing an additional 20,638 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CAPR. HC Wainwright reissued a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Roth Capital started coverage on shares of Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.50.

Capricor Therapeutics Stock Up 8.0%

NASDAQ:CAPR traded up $1.05 on Friday, reaching $14.23. 2,495,546 shares of the company's stock were exchanged, compared to its average volume of 1,780,198. The firm has a market capitalization of $649.98 million, a price-to-earnings ratio of -13.42 and a beta of 0.84. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The business has a fifty day moving average of $10.32 and a 200-day moving average of $12.96.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. During the same period in the previous year, the company earned ($0.31) earnings per share. As a group, equities analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.